Base de dados : MEDLINE
Pesquisa : D27.505.519.625.050.200 [Categoria DeCS]
Referências encontradas : 990 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 99 ir para página                         

  1 / 990 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28716301
[Au] Autor:Hasan S; Mosier MJ; Szilagyi A; Gamelli RL; Muthumalaiappan K
[Ad] Endereço:Department of Surgery, Loyola University Chicago, Health Sciences Division, Maywood, IL; Burn and Shock Trauma Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL.
[Ti] Título:Discrete ß-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia.
[So] Source:Surgery;162(4):901-916, 2017 Oct.
[Is] ISSN:1532-7361
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by ß1/ß2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of ß1/ß2, ß-2, or ß-3 blockade in burn mediated erythropoietin-resistant anemia. METHODS: Burn mice were randomized to receive daily injections of propranolol (nonselective ß1/ß2 antagonist), nadolol (long-acting ß1/ß2 antagonist), butoxamine (selective ß2 antagonist), or SR59230A (selective ß3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells. RESULTS: Although propranolol improved early and late erythroblasts, only butoxamine and selective ß3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, ß1/ß2 antagonism increased the early erythroblasts through commitment stages via ß2 specific MafB regulation. ß3 antagonism was more effective in improving overall red blood cells through late maturation stages. CONCLUSION: The study unfolds novel ß2 and ß3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.
[Mh] Termos MeSH primário: Anemia/etiologia
Queimaduras/complicações
Eritropoese
Receptores Adrenérgicos beta/fisiologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos/farmacologia
Animais
Butoxamina/farmacologia
Modelos Animais de Doenças
Masculino
Camundongos
Nadolol/farmacologia
Propanolaminas/farmacologia
Propranolol/farmacologia
Receptores Adrenérgicos beta/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate); 0 (Adrenergic Antagonists); 0 (Propanolamines); 0 (Receptors, Adrenergic, beta); 0NM31M53PW (Butoxamine); 42200-33-9 (Nadolol); 9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE


  2 / 990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28406051
[Au] Autor:Siddiqui PJA; Khan A; Uddin N; Khaliq S; Rasheed M; Nawaz S; Hanif M; Dar A
[Ad] Endereço:a Centre of Excellence in Marine Biology, University of Karachi , Karachi , Pakistan.
[Ti] Título:Antidepressant-like deliverables from the sea: evidence on the efficacy of three different brown seaweeds via involvement of monoaminergic system.
[So] Source:Biosci Biotechnol Biochem;81(7):1369-1378, 2017 Jul.
[Is] ISSN:1347-6947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Brown seaweeds exhibit several health benefits in treating and managing wide array of ailments. In this study, the antidepressant-like effect of methaolic extracts from Sargassum swartzii (SS), Stoechospermum marginatum (SM), and Nizamuddinia zanardinii (NZ) was examined in forced swimming test (FST), in rats. Oral administration of SS, SM, and NZ extract (30-60 mg/kg) exhibited antidepressant-like activity in FST by reducing immobility time as compared to control group, without inducing significant change in ambulatory behavior in open field test. In order to evaluate the involvement of monoaminergic system, rats were pretreated with the inhibitor of brain serotonin stores p-chlorophenylalanin (PCPA), dopamine (SCH23390 and sulpiride), and adrenoceptor (prazosin and propranolol) antagonists. Rats receiving treatment for 28 days were decapitated and brains were analyzed for monoamine levels. It may be concluded that the extracts of SS, SM, and NZ produces antidepressant-like activity via modulation of brain monoaminergic system in a rat model.
[Mh] Termos MeSH primário: Antidepressivos/farmacologia
Depressão/prevenção & controle
Feófitas/química
Receptores Adrenérgicos/genética
Receptores Dopaminérgicos/genética
Receptores de Serotonina/genética
Alga Marinha/química
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos/farmacologia
Animais
Antidepressivos/isolamento & purificação
Benzazepinas/farmacologia
Depressão/genética
Depressão/metabolismo
Depressão/fisiopatologia
Antagonistas de Dopamina/farmacologia
Fenclonina/farmacologia
Regulação da Expressão Gênica/efeitos dos fármacos
Masculino
Aprendizagem em Labirinto/efeitos dos fármacos
Metanol
Prazosina/farmacologia
Propranolol/farmacologia
Ratos
Ratos Wistar
Receptores Adrenérgicos/metabolismo
Receptores Dopaminérgicos/metabolismo
Receptores de Serotonina/metabolismo
Antagonistas da Serotonina/farmacologia
Solventes
Sulpirida/farmacologia
Natação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Antagonists); 0 (Antidepressive Agents); 0 (Benzazepines); 0 (Dopamine Antagonists); 0 (Receptors, Adrenergic); 0 (Receptors, Dopamine); 0 (Receptors, Serotonin); 0 (SCH 23390); 0 (Serotonin Antagonists); 0 (Solvents); 7MNE9M8287 (Sulpiride); 9Y8NXQ24VQ (Propranolol); R5J7E3L9SP (Fenclonine); XM03YJ541D (Prazosin); Y4S76JWI15 (Methanol)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1080/09168451.2017.1313697


  3 / 990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28195064
[Au] Autor:Filippi A; Caruntu C; Gheorghe RO; Deftu A; Amuzescu B; Ristoiu V
[Ad] Endereço:Department of Medical Biophysics, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania.
[Ti] Título:Catecholamines reduce transient receptor potential vanilloid type 1 desensitization in cultured dorsal root ganglia neurons.
[So] Source:J Physiol Pharmacol;67(6):843-850, 2016 Dec.
[Is] ISSN:1899-1505
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Sympathetic nervous system and adrenergic receptors are involved in the modulation of dorsal root ganglia neuronal activity, with TRPV1 receptor as an important downstream effector. It is already known that adrenergic sensitization of TRPV1 receptors or catecholamine-induced TRPV1 upregulation are involved in increased excitability and pain via mainly α adrenergic receptors, but it is not known if reduced TRPV1 desensitization is involved in this process, as well. Therefore, the aims of this study were to evaluate the effects of epinephrine and norepinephrine on TRPV1 desensitization induced by repeated applications of capsaicin and to assess what would be the involvement of the major α , α and ß adrenergic receptor subtypes. Using calcium microfluorimetry, the effects were evaluated by exposure to 1 µM epinephrine or 10 µM norepinephrine, alone or in the presence of adrenergic receptor inhibitors (phentolamine, prazosin and propranolol) before a 4 capsaicin application in a series of 5 consecutive capsaicin applications. The results showed that both catecholamines produced significant reduction of TRPV1 desensitization, which was mediated by α , α and ß receptors. This study completes the general information about TRPV1 sensitization via adrenergic stimulation and may open perspectives for novel pharmacological approaches in skin inflammatory disorders and pain therapy.
[Mh] Termos MeSH primário: Catecolaminas/farmacologia
Gânglios Espinais/efeitos dos fármacos
Gânglios Espinais/metabolismo
Neurônios/efeitos dos fármacos
Neurônios/metabolismo
Canais de Cátion TRPV/metabolismo
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos/farmacologia
Animais
Cálcio/metabolismo
Capsaicina/farmacologia
Células Cultivadas
Epinefrina/farmacologia
Inflamação/tratamento farmacológico
Inflamação/metabolismo
Masculino
Norepinefrina/farmacologia
Dor/tratamento farmacológico
Dor/metabolismo
Ratos
Ratos Wistar
Receptores Adrenérgicos/metabolismo
Pele/efeitos dos fármacos
Pele/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Antagonists); 0 (Catecholamines); 0 (Receptors, Adrenergic); 0 (TRPV Cation Channels); 0 (Trpv1 protein, rat); S07O44R1ZM (Capsaicin); SY7Q814VUP (Calcium); X4W3ENH1CV (Norepinephrine); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170608
[Lr] Data última revisão:
170608
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170215
[St] Status:MEDLINE


  4 / 990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28018865
[Au] Autor:Dong Y; Liu J; Pang M; Du H; Wang N; Awan F; Lu C; Liu Y
[Ad] Endereço:Department of Preventive Veterinary, College of Veterinary Medicine, Nanjing Agricultural University Nanjing, China.
[Ti] Título:Catecholamine-Stimulated Growth of Requires the TonB2 Energy Transduction System but Is Independent of the Amonabactin Siderophore.
[So] Source:Front Cell Infect Microbiol;6:183, 2016.
[Is] ISSN:2235-2988
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The growth-stimulating effects of catecholamine stress hormones have been demonstrated in many pathogens. However, catecholamine-induced growth and its underlying mechanisms remain poorly understood in . The present study sought to demonstrate that norepinephrine (NE), epinephrine (Epi), dopamine (Dopa), and L-dopa stimulate the growth of in iron-restricted media containing serum. NE exhibited the strongest growth stimulation, which could be blocked by adrenergic antagonists. Furthermore, it was demonstrated that NE could sequester iron from transferrin, thereby providing a more accessible iron source for utilization by . The deletion of the gene associated with amonabactin synthesis revealed that the amonabactin siderophore is not required for NE-stimulated growth. However, the deletion of the TonB2 energy transduction system resulted in the loss of growth promotion by NE, indicating that a specific TonB-dependent outer membrane receptor might be involved in the transport of iron from transferrin. Collectively, our data show that catecholamine sensing promotes the growth of in a manner that is dependent on the TonB2 energy transduction system.
[Mh] Termos MeSH primário: Aeromonas hydrophila/efeitos dos fármacos
Aeromonas hydrophila/crescimento & desenvolvimento
Catecolaminas/farmacologia
Sideróforos/metabolismo
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos
Aeromonas hydrophila/metabolismo
Animais
Proteínas da Membrana Bacteriana Externa/metabolismo
Biofilmes/crescimento & desenvolvimento
Proteínas de Transporte
Linhagem Celular
DNA Bacteriano/genética
Dopamina/farmacologia
Epinefrina/farmacologia
Escherichia coli/genética
Feminino
Genes Bacterianos
Ferro/metabolismo
Levodopa/farmacologia
Camundongos
Camundongos Endogâmicos ICR
Norepinefrina/farmacologia
Oligopeptídeos/metabolismo
Deleção de Sequência
Transdução de Sinais
Estresse Psicológico
Transferrina/química
Transferrina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Antagonists); 0 (Bacterial Outer Membrane Proteins); 0 (Carrier Proteins); 0 (Catecholamines); 0 (DNA, Bacterial); 0 (Oligopeptides); 0 (Siderophores); 0 (Transferrin); 46627O600J (Levodopa); E1UOL152H7 (Iron); VTD58H1Z2X (Dopamine); X4W3ENH1CV (Norepinephrine); YKH834O4BH (Epinephrine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161227
[St] Status:MEDLINE
[do] DOI:10.3389/fcimb.2016.00183


  5 / 990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27678409
[Au] Autor:Zoccarato A; Fields LH; Zaccolo M
[Ad] Endereço:Department of Cardiology, Cardiovascular Division, British Heart Foundation Centre, King's College London, London, UK.
[Ti] Título:Response to Wagner et al.: phosphodiesterase-2-anti-adrenergic friend or hypertrophic foe in heart disease?
[So] Source:Naunyn Schmiedebergs Arch Pharmacol;389(11):1143-1145, 2016 Nov.
[Is] ISSN:1432-1912
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos
Cardiopatias
[Mh] Termos MeSH secundário: Seres Humanos
Hipertrofia
Diester Fosfórico Hidrolases
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Adrenergic Antagonists); EC 3.1.4.- (Phosphoric Diester Hydrolases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160929
[St] Status:MEDLINE


  6 / 990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27664442
[Au] Autor:Kinuthia DG; Muriithi AW; Mwangi PW
[Ad] Endereço:Department of Medical Physiology, School of Medicine, University of Nairobi, P.O. Box 30197-00100, Nairobi, Kenya. Electronic address: gachkin@gmail.com.
[Ti] Título:Freeze dried extracts of Bidens biternata (Lour.) Merr. and Sheriff. show significant antidiarrheal activity in in-vivo models of diarrhea.
[So] Source:J Ethnopharmacol;193:416-422, 2016 Dec 04.
[Is] ISSN:1872-7573
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:ETHNOPHARMACOLOGICAL RELEVANCE OF THE STUDY: Diarrhea remains one of the main killers of children aged below five years. Traditional antidiarrheal remedies form a potentially viable source of novel low cost efficacious treatments in low resource settings. There is therefore a pressing need to scientifically evaluate these remedies. AIM OF THE STUDY: This study aimed to investigate the in vivo and in vitro antidiarrheal activity of freeze dried Bidens biternata, a herb used in traditional Ayurvedic medicine in the management of diarrhea. MATERIALS AND METHODS: In the castor oil test, twenty (20) adult Sprague-Dawley rats were randomized to a negative control (normal saline, n=5), a positive control (5mg/kg loperamide, n=5), and two test groups. The low dose test group received 200mg/kg Bidens biternata extract (n=5) while the high dose test group received 400mg/kg B. biternata extract (n=5). Castor oil (4ml/kg) was then administered to the animals one hour after administration of the respective treatments after which the total mass of fecal output excreted after four (4) hours was determined. In the charcoal meal test fifteen (15) Sprague Dawley rats were randomized to a control group (normal saline 5ml/kg orally, n=5), a positive control group (atropine sulfate 0.1mg/kg i.p., n=5) and a test group (400mg/kg B. biternata extract, n=5). Charcoal meal was then administered via oral gavage to each rat thirty (30) minutes after the administration of the various treatments. The distance covered by the charcoal meal from the pylorus was then determined after sacrifice of the animals thirty minutes after the meal. In the enteropooling test twenty (20) Sprague-Dawley rats were randomized to a control group (5% v/v ethanol in normal saline, n=5), a positive control group (5mg/kg loperamide, n=5) and a test group (400mg/kg B. biternata extract, n=5). For each group prostaglandin E2 (PGE2) (100µg/kg) was administered immediately after the treatments. The animals were then sacrificed half an hour later and the volume of the small intestine contents determined. The effects of different concentrations of B. biternata extract (0.5. 1.0, 2.0, 3.0 and 5.0mg/ml) on jejunal contraction were investigated and a dose-response curve constructed using the experimental data after which The ED50 dose was determined. The effect of tamsulosin (α1 adrenergic blocker), yohimbine (α2 adrenergic blocker), propranolol (ß adrenergic blocker) and naloxone (µ opioid blocker) on the contractile activity of the extract were also investigated. The experimental data were expressed as mean±standard error of mean (SEM) and then analyzed using one-way ANOVA followed by Tukey's post hoc test in cases of significance (set at p<0.05). RESULTS: The freeze dried extracts of B. biternata had significant antidiarrheal effects in the castor oil induced diarrhea model (p<0.01) with the highest activity being observed at the 400mg/kg dosage level (1.66±0.81g vs. 4.54±0.51g control, p=0.01). B. biternata extract had significant effects on intestinal motility in the charcoal meal test compared to the control group (43.61±4.42% vs. 60.54±3.33%: p<0.05). B. biternata extract had a significant effect on PGE2 induced enteropooling (3.06±0.07ml vs. 4.74±0.10ml; p<0.001). The freeze dried extracts of B. biternata had a significant negative effect on the contractility of the isolated rabbit jejunum (p<0.001). The effects of the extract were significantly attenuated by tamsulosin (53.94±4.20% vs. 80.57±4.09%; p<0.01) and naloxone (53.94±4.20% vs. 73.89±7.26%; p<0.05). Yohimbine (p>0.05) and propranolol (p>0.05) however did not have any significant effect on the contractile activity of the extract. CONCLUSIONS: The freeze dried extract of B. biternata possess significant antidiarrheal activity in both in vitro and in vivo models which appears to be mediated by modulating both the intestinal motility as well as the secretory activity. The results of this study also validate its traditional use as an antidiarrheal remedy.
[Mh] Termos MeSH primário: Antidiarreicos/farmacologia
Bidens/química
Defecação/efeitos dos fármacos
Diarreia/tratamento farmacológico
Liofilização
Motilidade Gastrointestinal/efeitos dos fármacos
Jejuno/efeitos dos fármacos
Extratos Vegetais/farmacologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos/farmacologia
Animais
Antidiarreicos/química
Antidiarreicos/isolamento & purificação
Óleo de Rícino
Diarreia/induzido quimicamente
Diarreia/metabolismo
Diarreia/fisiopatologia
Dinoprostona/metabolismo
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Técnicas In Vitro
Secreções Intestinais/metabolismo
Jejuno/metabolismo
Jejuno/fisiopatologia
Loperamida/farmacologia
Masculino
Antagonistas de Entorpecentes/farmacologia
Fitoterapia
Componentes Aéreos da Planta
Extratos Vegetais/química
Extratos Vegetais/isolamento & purificação
Plantas Medicinais
Coelhos
Ratos Sprague-Dawley
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Antagonists); 0 (Antidiarrheals); 0 (Narcotic Antagonists); 0 (Plant Extracts); 6X9OC3H4II (Loperamide); 8001-79-4 (Castor Oil); K7Q1JQR04M (Dinoprostone)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160925
[St] Status:MEDLINE


  7 / 990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27663545
[Au] Autor:Xu W; Huang J; Shao B; Xu X; Jiang R; Yuan M
[Ad] Endereço:School of Pharmaceutical Sciences, Jinan University, Guangzhou 510632, China.
[Ti] Título:Design, synthesis, crystal structure, biological evaluation and molecular docking studies of carbazole-arylpiperazine derivatives.
[So] Source:Bioorg Med Chem;24(21):5565-5572, 2016 Nov 01.
[Is] ISSN:1464-3391
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Subtype-selective α -adrenoceptor (AR) antagonists display optimum therapeutic efficacies for the treatment of benign prostatic hyperplasia (BPH). In this study, we designed and synthesized novel carbazole-arylpiperazines derivatives (1 and 2) on the basis of the proposed pharmacophore model for α -AR antagonists. Structural properties were investigated using single-crystal X-ray diffraction analysis. Comparison of crystal structures with ligand-based pharmacophore models revealed that the two agents may possess antagonistic effects on α subtype. Tissue functional assay in vitro showed that compound 2 exerted strong antagonistic activity on α -AR (pA 7.13) with a poor selectivity for α and α subtypes. Compound 1 exhibited enhanced antagonistic effect on α subtype (pA 7.06) and excellent selectivity for α over α (α /α ratio=79.4). To illustrate the relationship between antagonistic activity and chemical structure, molecular docking studies were performed using the homology models of α receptors. Binding mechanism indicated that small hydrophobic substituents attached to the arylpiperazine moiety were essential for rational design of α -selective antagonists.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos/síntese química
Antagonistas Adrenérgicos/farmacologia
Carbazóis/farmacologia
Desenho de Drogas
Piperazinas/farmacologia
Receptores Adrenérgicos alfa 1/metabolismo
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos/química
Carbazóis/química
Cristalografia por Raios X
Relação Dose-Resposta a Droga
Seres Humanos
Modelos Moleculares
Estrutura Molecular
Piperazinas/química
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Antagonists); 0 (Carbazoles); 0 (Piperazines); 0 (Receptors, Adrenergic, alpha-1); 0P2197HHHN (carbazole)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160925
[St] Status:MEDLINE


  8 / 990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27574770
[Au] Autor:Onasanwo SA; Faborode SO; Ilenre KO
[Ad] Endereço:Neurosciences and Oral Physiology Unit, Department of Physiology, University of Ibadan, Ibadan. samphil2002@yahoo.com.
[Ti] Título:Antidepressant-like Potentials of Buchholzia Coriacea Seed Extract: Involvement of Monoaminergic and Cholinergic Systems, and Neuronal Density in the Hippocampus of Adult Mice.
[So] Source:Niger J Physiol Sci;31(1):93-9, 2016 Aug 30.
[Is] ISSN:0794-859X
[Cp] País de publicação:Nigeria
[La] Idioma:eng
[Ab] Resumo:Buchholzia coriacea, taken by elderly, has phytochemicals that have neuro-active metabolites, and the folkloredocumented its use in neuro-behavioral despairs. Previous study in our laboratory shows that methanol extracts of Buchholziacoriacea (MEBC) seeds possess antidepressant-like potentials in laboratory rodents. This present study was conducted toinvestigate the probable mechanism(s) of action by which MEBC potentiates its effects using laboratory rodents.Involvements of serotonergic, cholinergic and adrenergic systems were studied using Forced Swimming Test (FST) and TailSuspension Test (TST) models of behavioral despair. Antagonists which including: Prazosin, an alpha-1-adrenergic receptorblocker (62.5 µg/kg, i.p.), metergoline, a 5HT2 receptor blocker (4 mg/kg, i.p.) and atropine, a -muscarinic cholinergicreceptor blocker (1mg/kg i.p.) were administered before effective dose of MEBC (50mg/kg). Also, the hippocampi of theanimals were studied for changes in neuronal density using Nissl Staining. Our findings showed that mobility was reversedin animals pre-treated with atropine, prazosin, and metergoline significantly (PË‚0.05), showing a possible involvement ofthe corresponding systems. However, there was a significant reduction in immobility time (P<0.001) during FST afterchronic administration of the MEBC. The hippocampus showed no significant changes (P<0.05) in neuronal density. Inconclusion, MEBC probably potentiates its antidepressant-like potentials via the cholinergic, adrenergic and partly byserotonergic systems.
[Mh] Termos MeSH primário: Antidepressivos/farmacologia
Monoaminas Biogênicas/antagonistas & inibidores
Capparaceae
Hipocampo/citologia
Antagonistas Muscarínicos/farmacologia
Extratos Vegetais/farmacologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos/farmacologia
Animais
Antidepressivos/isolamento & purificação
Feminino
Hipocampo/efeitos dos fármacos
Camundongos
Neurônios/efeitos dos fármacos
Extratos Vegetais/isolamento & purificação
Sementes
Antagonistas da Serotonina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Antagonists); 0 (Antidepressive Agents); 0 (Biogenic Monoamines); 0 (Muscarinic Antagonists); 0 (Plant Extracts); 0 (Serotonin Antagonists)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170313
[Lr] Data última revisão:
170313
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160831
[St] Status:MEDLINE


  9 / 990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27571333
[Au] Autor:Riccio C; Gulizia MM; Colivicchi F; Di Lenarda A; Musumeci G; Faggiano PM; Abrignani MG; Rossini R; Fattirolli F; Valente S; Mureddu GF; Temporelli PL; Olivari Z; Amico AF; Casolo G; Fresco C; Menozzi A; Nardi F
[Ad] Endereço:U.O.C. Cardiologia Clinica e Riabilitazione Cardiologica, A.O. Sant'Anna e San Sebastiano, Caserta.
[Ti] Título:[ANMCO/GICR-IACPR/SICI-GISE Consensus document: Clinical management of patients with stable coronary artery disease].
[Ti] Título:Documento di consenso ANMCO/GICR-IACPR/SICI-GISE: La gestione clinica del paziente con cardiopatia ischemica cronica..
[So] Source:G Ital Cardiol (Rome);17(7-8):529-69, 2016 Jul-Aug.
[Is] ISSN:1827-6806
[Cp] País de publicação:Italy
[La] Idioma:ita
[Ab] Resumo:Stable coronary artery disease is of epidemiological importance. It is becoming increasingly common due to the longer life expectancy, being strictly related to age and to advances in diagnostic techniques and pharmacological and non-pharmacological interventions.Stable coronary artery disease encompasses a variety of clinical and anatomic presentations, making the identification of its clinical and anatomical features challenging. Therapeutic interventions should be defined on an individual basis according to the patient's risk profile. To this aim, management flow-charts have been reviewed based on sustainability and appropriateness derived from recent evidence. Special emphasis has been placed on non-pharmacological interventions, stressing the importance of lifestyle changes, including smoking cessation, regular physical activity and diet. Adherence to therapy as an emerging risk factor is also discussed.
[Mh] Termos MeSH primário: Angioplastia Coronária com Balão
Ponte de Artéria Coronária
Doença da Artéria Coronariana/terapia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos/uso terapêutico
Angioplastia Coronária com Balão/métodos
Anti-Inflamatórios não Esteroides/uso terapêutico
Bloqueadores dos Canais de Cálcio/uso terapêutico
Fármacos Cardiovasculares/uso terapêutico
Ponte de Artéria Coronária/métodos
Doença da Artéria Coronariana/diagnóstico
Doença da Artéria Coronariana/epidemiologia
Doença da Artéria Coronariana/prevenção & controle
Quimioterapia Combinada
Seres Humanos
Itália/epidemiologia
Cooperação do Paciente
Inibidores da Agregação de Plaquetas/uso terapêutico
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic Antagonists); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Calcium Channel Blockers); 0 (Cardiovascular Agents); 0 (Platelet Aggregation Inhibitors)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170207
[Lr] Data última revisão:
170207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160830
[St] Status:MEDLINE
[do] DOI:10.1714/2330.25050


  10 / 990 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27457085
[Au] Autor:Hensey M; O'Neill J
[Ad] Endereço:Connolly Hospital Blanchardstown, Blanchardstown, Dublin 15, Dublin, Ireland.
[Ti] Título:Is Heart Rate a Norepiphenomenon in Heart Failure?
[So] Source:Curr Cardiol Rep;18(9):91, 2016 Sep.
[Is] ISSN:1534-3170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There has been an increased focus on heart rate as a target in the management of cardiovascular disease and more specifically in heart failure with preserved ejection fraction in recent years with several studies showing the benefit of a lower resting heart rate on outcomes. This review paper examines the pathophysiology behind the benefits of lowering heart rate in heart failure and also the evidence for and against the pharmacological agents available to achieve this.
[Mh] Termos MeSH primário: Insuficiência Cardíaca/fisiopatologia
Frequência Cardíaca/fisiologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos/farmacologia
Amiodarona/farmacologia
Benzazepinas/farmacologia
Depressão Química
Digoxina/farmacologia
Medicina Baseada em Evidências/métodos
Insuficiência Cardíaca/tratamento farmacológico
Frequência Cardíaca/efeitos dos fármacos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic Antagonists); 0 (Benzazepines); 3H48L0LPZQ (ivabradine); 73K4184T59 (Digoxin); N3RQ532IUT (Amiodarone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160727
[St] Status:MEDLINE
[do] DOI:10.1007/s11886-016-0764-3



página 1 de 99 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde